Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EL219 (Turletricin) vs LAmB or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections
NCT07215273Phase 2Recruiting
- Sponsor
- Elion Therapeutics
- Start
- Feb 2026
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of turletricin in invasive mould infection (IMI), sponsored by Elion Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
turletricin
03
Conditions
invasive mould infection (IMI)
Beyond the preview
Go deeper on NCT07215273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07215273.